No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Theravance Biopharma to Participate in an Upcoming Investor Conference
Theravance Biopharma | 10-Q: Q1 2025 Earnings Report
Shareholders Will Probably Hold Off On Increasing Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For The Time Being
H.C. Wainwright Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Maintains Target Price $15
BTIG Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Maintains Target Price $24
Theravance Biopharma Reports Strong Growth and Optimism